Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 51

Sort by

Sort Order Select

Journal Articles

The Treatment of Burkitt Lymphoma with the Berlin-Frankfurt-Münster Protocol with Rituximab and Autologous Transplantation

Alessandro Broccoli, Gianmarco Bagnato, Lisa Argnani, Beatrice Casadei, Martina Cantelli, Cinzia Pellegrini, Sabrina Zoli, Emanuele Sutto, Paolo Elia Coppola, Marianna Gentilini, Alice Morigi, Matteo Carella, Gabriele Gugliotta, Laura Nanni, Vittorio Stefoni, Pier Luigi Zinzani

Blood (2023) 142 (Supplement 1): 6290.

https://doi.org/10.1182/blood-2023-178586

Published: 2023

Journal Articles

Role of Pegylated Liposomal Doxorubicin in Heavily Pretreated Relapsed Refractory Hodgkin Lymphoma Eligible for Autologous or Allogeneic Transplantation

Beatrice Casadei, Cinzia Pellegrini, Emanuele Sutto, Martina Cantelli, Lisa Argnani, Sabrina Zoli, Paolo Elia Coppola, Marianna Gentilini, Alice Morigi, Matteo Carella, Gabriele Gugliotta, Gianmarco Bagnato, Laura Nanni, Alessandro Broccoli, Vittorio Stefoni, Pier Luigi Zinzani

Blood (2023) 142 (Supplement 1): 6204.

https://doi.org/10.1182/blood-2023-178601

Published: 2023

Journal Articles

Prognostic Impact of Pre-Treatment Cell-Free DNA Concentration in Newly Diagnosed Peripheral T-Cell Lymphomas

Eugenio Fardella, Giada Zanirato, Martina Magni, Nicole Caldarelli, Annalisa Chiappella, Anna Dodero, Silva Ljevar, Lorella Orsucci, Alessandro Re, Sara Usai, Vittorio Stefoni, Claudia Castellino, Francesca Gaia Rossi, Antonio Pinto, Cristiana Carniti, Paolo Corradini

Blood (2023) 142 (Supplement 1): 1695.

https://doi.org/10.1182/blood-2023-189215

Published: 2023

Journal Articles

MRD Monitoring By Euroclonality IGH Based NGS Approach Predicts Outcome in Follicular Lymphoma Patients Lacking a Conventional BCL2::IGH Marker: A Substudy from the Fondazione Italiana Linfomi (FIL) FOLL12 Trial

Blood (2023) 142 (Supplement 1): 4373.

https://doi.org/10.1182/blood-2023-181813

Published: 2023

Journal Articles

The Clinical Complexity of Langherans Cell Histiocytosis in Adult Patients: Experience of the Institute of Hematology of Bologna

Alessandro Broccoli, Gianmarco Bagnato, Lisa Argnani, Martina Cantelli, Beatrice Casadei, Cinzia Pellegrini, Sabrina Zoli, Emanuele Sutto, Paolo Elia Coppola, Marianna Gentilini, Alice Morigi, Matteo Carella, Gabriele Gugliotta, Laura Nanni, Vittorio Stefoni, Pier Luigi Zinzani

Blood (2023) 142 (Supplement 1): 6412.

https://doi.org/10.1182/blood-2023-178573

Published: 2023

Journal Articles

Design of New Personalized Therapeutic Approaches for Diffuse Large B-Cell Lymphoma through Gut Microbiome Profiling

Laura Nanni, Gerardo Musuraca, Alice Morigi, Vittorio Stefoni, Monica Barone, Gabriele Conti, Marco Fabbrini, Silvia Turroni, Alessandro Broccoli, Lisa Argnani, Patrizia Brigidi, Pier Luigi Zinzani

Blood (2022) 140 (Supplement 1): 4961–4963.

https://doi.org/10.1182/blood-2022-158175

Published: 2022

Journal Articles

Dissecting MRD Kinetics By Automated Computational Analysis to Improve Outcome Prediction in Mantle Cell Lymphoma: A Bioinformatic Substudy from the Fondazione Italiana Linfomi (FIL) MCL0208 Clinical Trial

Blood (2022) 140 (Supplement 1): 9375–9377.

https://doi.org/10.1182/blood-2022-159949

Published: 2022

Journal Articles

The Addition of Romidepsin to CHOEP and High-Dose Chemotherapy Plus Stem Cell Transplantation Did Not Ameliorate the Outcome of Untreated Angioimmunoblastic T-Cell or Follicular T-Helper Lymphoma: Subgroup Analysis of Phase II FIL-PTCL13 Study

Blood (2022) 140 (Supplement 1): 6538–6539.

https://doi.org/10.1182/blood-2022-163824

Published: 2022

Journal Articles

Rituximab As an Effective Salvage Therapy in Pretreated Hairy Cell Leukemia Patients: The Bologna Experience

Alessandro Broccoli, Lisa Argnani, Laura Nanni, Gianmarco Bagnato, Matteo Carella, Beatrice Casadei, Paolo Elia Coppola, Gabriele Gugliotta, Ginevra Lolli, Marianna Gentilini, Alice Morigi, Cinzia Pellegrini, Vittorio Stefoni, Pier Luigi Zinzani

Blood (2022) 140 (Supplement 1): 6526–6527.

https://doi.org/10.1182/blood-2022-158158

Published: 2022

Journal Articles

Adding Romidepsin to CHOEP in First Line Treatment of Peripheral T-Cell Lymphomas Does Not Improve the Response Rate: Final Analysis of Phase II PTCL13 Study

Blood (2021) 138 (Supplement 1): 134.

https://doi.org/10.1182/blood-2021-153680

Published: 2021

Journal Articles

Brentuximab Vedotin As Single Agent in the Treatment of Relapsed/Refractory CD30 Positive Peripheral T-Cell Lymphoma Patients: A Phase 2 Study of the Fondazione Italiana Linfomi

Vittorio Stefoni, MD PhD, Paolo Corradini, Lorella Orsucci, MD, Stefano Volpetti, Lisa Argnani, Anna Dodero, Cinzia Pellegrini, Pier Luigi Zinzani, MD

Blood (2020) 136 (Supplement 1): 21.

https://doi.org/10.1182/blood-2020-136917

Published: 2020

Journal Articles

Final Analysis of the Ro-CHOP Phase III Study (Conducted by LYSA): Romidepsin Plus CHOP in Patients with Peripheral T-Cell Lymphoma

Blood (2020) 136 (Supplement 1): 32–33.

https://doi.org/10.1182/blood-2020-134440

Published: 2020

Journal Articles

Pharmacogenomics Drives Lenalidomide Efficacy and MRD Kinetics in Mantle Cell Lymphoma after Autologous Transplantation: Results from the MCL0208 Multicenter, Phase III, Randomized Clinical Trial from the Fondazione Italiana Linfomi (FIL)

Blood (2020) 136 (Supplement 1): 16–17.

https://doi.org/10.1182/blood-2020-134875

Published: 2020

Journal Articles

The Treatment of Hairy Cell Leukemia with a Focus on Long Lasting Responders to Cladribine: A Thirty-Year Experience from the Institute of Hematology of Bologna

Alessandro Broccoli, Carolina Terragna, Vittorio Stefoni, Cinzia Pellegrini, Beatrice Casadei, MD, Miriam Marangon, Alice Morigi, Laura Nanni, MD, Ginevra Lolli, Matteo Carella, Lisa Argnani, Michele Cavo, Pier Luigi Zinzani, MD PhD

Blood (2019) 134 (Supplement_1): 4005.

https://doi.org/10.1182/blood-2019-122832

Published: 2019

Journal Articles

Romidepsin-CHOEP Plus Intensification with up-Front Stem-Cell Transplantation in Peripheral T-Cell Lymphoma: Final Results of Phase Ib PTCL13 Study of the Fondazione Italiana Linfomi

Annalisa Chiappella, MD, Cristiana Carniti, Andrea Evangelista, PhD, Maria Giuseppina Cabras, MD, Alessandro Re, MD, Manuela Zanni, MD, Vittorio Stefoni, Armando Santoro, MD, Angela Giovanna Congiu, Anna Dodero, MD, Stefano A. Pileri, MD PhD, Giovannino Ciccone, MD, Paolo Corradini, MD

Blood (2018) 132 (Supplement 1): 2902.

https://doi.org/10.1182/blood-2018-99-119763

Published: 2018

Journal Articles

A Phase II Study of Brentuximab Vedotin (BV) in the Treatment of Elderly Hodgkin Lymphoma (HL) Patients at First Relapse or with Primary Refractory Disease — FIL_BVHD01

Lorenzo Tonialini, MD, Vittorio Stefoni, Alessandro Re, MD, Arben Lleshi, MD, Maurizio Bonfichi, MD, Antonello Pinto, Nicola Bianchetti, Lisa Argnani, Pier Luigi Zinzani, MD

Blood (2018) 132 (Supplement 1): 2920.

https://doi.org/10.1182/blood-2018-99-111812

Published: 2018

Journal Articles

Lenalidomide Maintenance after Autologous Transplantation Prolongs PFS in Young MCL Patients: Results of the Randomized Phase III MCL 0208 Trial from Fondazione Italiana Linfomi (FIL)

Blood (2018) 132 (Supplement 1): 401.

https://doi.org/10.1182/blood-2018-99-110289

Published: 2018

Journal Articles

The Bbv Regimen: A Phase II Study with Bendamustine Plus Brentuximab Vedotin in Hodgkin Lymphoma and CD30+ Peripheral T-Cell Lymphoma in First Salvage Setting

Vittorio Stefoni, Beatrice Casadei, MD, Barbara Botto, Paolo Corradini, MD, Antonello Pinto, Alessandro Re, MD, Stefania Badiali, Lisa Argnani, Pier Luigi Zinzani, MD PhD

Blood (2017) 130 (Supplement 1): 4087.

https://doi.org/10.1182/blood.V130.Suppl_1.4087.4087

Published: 2017

Journal Articles

Brentuximab vedotin in relapsed primary mediastinal large B-cell lymphoma: results from a phase 2 clinical trial

Pier Luigi Zinzani, Cinzia Pellegrini, Annalisa Chiappella, Alice Di Rocco, Flavia Salvi, Maria Giuseppina Cabras, Lisa Argnani, Vittorio Stefoni

Blood (2017) 129 (16): 2328–2330.

https://doi.org/10.1182/blood-2017-01-764258

Published: 2017

Journal Articles

Multicenter Retrospective Observational Study to Assess the Clinical Characteristics and the Outcome of Patients with Relapsed or Refractory Mantle Cell Non-Hodgkin's Lymphoma Treated in Italy According to the Ibrutinib Named Patient Program

Vittorio Stefoni, Federico Sottotetti, Manuel Gotti, Michele Spina, Stefano Volpetti, Simone Ferrero, Francesco Spina, MD, Francesco Pisani, Michele Merli, Carlo Visco, MD, Rossella Paolini, Vittorio Ruggero Zilioli, Luca Baldini, MD Prof, Nicola Di Renzo, Patrizia Tosi, Nicola Cascavilla, MD, Stefano Molica, MD, Lisa Argnani, Pier Luigi Zinzani, MD PhD

Blood (2016) 128 (22): 2985.

https://doi.org/10.1182/blood.V128.22.2985.2985

Published: 2016

NARROW

The Treatment of Burkitt Lymphoma with the Berlin-Frankfurt-Münster Protocol with Rituximab and Autologous Transplantation

Role of Pegylated Liposomal Doxorubicin in Heavily Pretreated Relapsed Refractory Hodgkin Lymphoma Eligible for Autologous or Allogeneic Transplantation

Prognostic Impact of Pre-Treatment Cell-Free DNA Concentration in Newly Diagnosed Peripheral T-Cell Lymphomas

MRD Monitoring By Euroclonality IGH Based NGS Approach Predicts Outcome in Follicular Lymphoma Patients Lacking a Conventional BCL2::IGH Marker: A Substudy from the Fondazione Italiana Linfomi (FIL) FOLL12 Trial

The Clinical Complexity of Langherans Cell Histiocytosis in Adult Patients: Experience of the Institute of Hematology of Bologna

Design of New Personalized Therapeutic Approaches for Diffuse Large B-Cell Lymphoma through Gut Microbiome Profiling

Dissecting MRD Kinetics By Automated Computational Analysis to Improve Outcome Prediction in Mantle Cell Lymphoma: A Bioinformatic Substudy from the Fondazione Italiana Linfomi (FIL) MCL0208 Clinical Trial

The Addition of Romidepsin to CHOEP and High-Dose Chemotherapy Plus Stem Cell Transplantation Did Not Ameliorate the Outcome of Untreated Angioimmunoblastic T-Cell or Follicular T-Helper Lymphoma: Subgroup Analysis of Phase II FIL-PTCL13 Study

Rituximab As an Effective Salvage Therapy in Pretreated Hairy Cell Leukemia Patients: The Bologna Experience

Adding Romidepsin to CHOEP in First Line Treatment of Peripheral T-Cell Lymphomas Does Not Improve the Response Rate: Final Analysis of Phase II PTCL13 Study

Brentuximab Vedotin As Single Agent in the Treatment of Relapsed/Refractory CD30 Positive Peripheral T-Cell Lymphoma Patients: A Phase 2 Study of the Fondazione Italiana Linfomi

Final Analysis of the Ro-CHOP Phase III Study (Conducted by LYSA): Romidepsin Plus CHOP in Patients with Peripheral T-Cell Lymphoma

Pharmacogenomics Drives Lenalidomide Efficacy and MRD Kinetics in Mantle Cell Lymphoma after Autologous Transplantation: Results from the MCL0208 Multicenter, Phase III, Randomized Clinical Trial from the Fondazione Italiana Linfomi (FIL)

The Treatment of Hairy Cell Leukemia with a Focus on Long Lasting Responders to Cladribine: A Thirty-Year Experience from the Institute of Hematology of Bologna

Romidepsin-CHOEP Plus Intensification with up-Front Stem-Cell Transplantation in Peripheral T-Cell Lymphoma: Final Results of Phase Ib PTCL13 Study of the Fondazione Italiana Linfomi

A Phase II Study of Brentuximab Vedotin (BV) in the Treatment of Elderly Hodgkin Lymphoma (HL) Patients at First Relapse or with Primary Refractory Disease — FIL_BVHD01

Lenalidomide Maintenance after Autologous Transplantation Prolongs PFS in Young MCL Patients: Results of the Randomized Phase III MCL 0208 Trial from Fondazione Italiana Linfomi (FIL)

The Bbv Regimen: A Phase II Study with Bendamustine Plus Brentuximab Vedotin in Hodgkin Lymphoma and CD30+ Peripheral T-Cell Lymphoma in First Salvage Setting

Brentuximab vedotin in relapsed primary mediastinal large B-cell lymphoma: results from a phase 2 clinical trial

Multicenter Retrospective Observational Study to Assess the Clinical Characteristics and the Outcome of Patients with Relapsed or Refractory Mantle Cell Non-Hodgkin's Lymphoma Treated in Italy According to the Ibrutinib Named Patient Program

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only